Status:

COMPLETED

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

Lead Sponsor:

AstraZeneca

Collaborating Sponsors:

Astra Zeneca, Bristol-Myers Squibb

Conditions:

Type 1 Diabetes Mellitus

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)

Detailed Description

Study Classification : Safety, Pharmacokinetics and Pharmacodynamics

Eligibility Criteria

Inclusion

  • Type 1 diabetes with central lab Glycosylated hemoglobin (A1C) ≥ 7.0% and ≤ 10.0%
  • Insulin use for at least 12 months and initiation immediately after diagnosis of diabetes
  • Method of Insulin administration \[multiple daily injections (MDI) or continuous subcutaneous Insulin infusion (CSII)\] stable ≥ 3 months
  • Stable basal Insulin dose ≥ 2 weeks
  • Ages 18 to 65 years
  • Central laboratory C-peptide value of \< 0.7 ng/mL
  • Body mass index (BMI) 18.5 to 35.0 kg/m2

Exclusion

  • History of type 2 diabetes mellitus (T2DM), maturity onset diabetes of young (MODY), pancreatic surgery or chronic pancreatitis
  • Oral hypoglycemic agents
  • History of diabetes ketoacidosis (DKA) within 24 weeks
  • History of hospital admission for glycemic control within 6 months
  • Frequent episodes of hypoglycemia (2 unexplained within 3 months) or hypoglycemic unawareness
  • Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) or Serum total bilirubin \> 2X Upper limit of normal (ULN)
  • Abnormal Free T4 \[if screening Thyroid Stimulating Hormone (TSH) abnormal\]
  • Estimated glomerular filtration rate (eGFR) Modification of Diet in Renal Disease (MDRD) formula ≤ 60 mL/min/1.73m2
  • Cardiovascular (CV)/Vascular Diseases within 6 months

Key Trial Info

Start Date :

February 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2012

Estimated Enrollment :

171 Patients enrolled

Trial Details

Trial ID

NCT01498185

Start Date

February 1 2012

End Date

October 1 2012

Last Update

February 10 2017

Active Locations (12)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (12 locations)

1

Profil Institute For Clinical Research, Inc.

Chula Vista, California, United States, 91911

2

Va San Diego Healthcare System

San Diego, California, United States, 92161

3

La Biomed Research Inst. At Harbor Ucla Med Ctr.

Torrance, California, United States, 90502

4

Compass Research Phase 1, Llc

Orlando, Florida, United States, 32806

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes | DecenTrialz